A growth hormone receptor mutation impairs growth hormone autofeedback signaling in pituitary tumors

Cancer Research

Volumn 67, Issue 15, 2007, Pages 7505-7511

  Asa, Sylvia L ^a,f   DiGiovanni, Rebecca ^a   Jiang, Jing ^c   Ward, Megan L ^a   Loesch, Kimberly ^c   Yamada, Shozo ^d   Sano, Toshiaki ^e   Yoshimoto, Katsuhiko ^d   Frank, Stuart J ^c   Ezzat, Shereen ^b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c University of Alabama at Birmingham   (United States)

^d TORANOMON HOSPITAL   (Japan)

^e UNIVERSITY OF TOKUSHIMA   (Japan)

^f UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; GROWTH HORMONE RECEPTOR; HISTIDINE; LEUCINE; SOMATOSTATIN DERIVATIVE;

ACROMEGALY; AGGRESOME; ARTICLE; CARCINOGENESIS; CLINICAL ARTICLE; CODON; CONTROLLED STUDY; CYTOSKELETON; DRUG ANTAGONISM; FEEDBACK SYSTEM; GENE MUTATION; GLYCOSYLATION; GROWTH HORMONE RELEASE; GROWTH HORMONE SECRETING ADENOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; LIGAND BINDING; MORPHOLOGY; PHENOTYPE; PRIORITY JOURNAL; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

ADENOMA; CARRIER PROTEINS; CELL PROLIFERATION; FEEDBACK, BIOCHEMICAL; HUMANS; IMMUNOENZYME TECHNIQUES; MUTAGENESIS, SITE-DIRECTED; MUTATION; PEPTIDE FRAGMENTS; PITUITARY NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 34547635253     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-0219     Document Type: Article

References (45)

1. Ezzat S, Asa SL, Couldwell WT, et al. The prevalence of pituitary adenomas: a systematic review. Cancer 2004;101:613-9.
2. Asa SL. Tumors of the pituitary gland. Atlas of tumor pathology, third series, fascicle 22. Washington (DC): Armed Forces Institute of Pathology; 1998.
3. Asa SL, Ezzat S. The pathogenesis of pituitary tumours. Nat Rev Cancer 2002;2:836-49.
4. Asa SL, Kovacs K. Functional morphology of the human fetal pituitary. Pathology Annual 1984;19 Pt 1:275-315.
5. Asa SL, Kovacs K, Laszlo FA, Domokos I, Ezrin C. Human fetal adenohypophysis. Histologic and immunocytochemical analysis. Neuroendocrinology 1986;43:308-16.
6. Asa SL. The role of hypothalamic hormones in the pathogenesis of pituitary adenomas. Pathol Res Pract 1991;187:581-3.
7. Landis CA, Masters SB, Spada A, Pace AM, Bourne HR, Vallar L. GTPase inhibiting mutations activate the α-chain of Gs and stimulate adenylate cyclase in human pituitary tumors. Nature 1989;340:692-6.
8. Lyons J, Landis CA, Harsh G, et al. Two G protein oncogenes in human endocrine tumors. Science 1990;249:655-9.
9. Spada A, Arosio M, Bochicchio D, et al. Clinical, biochemical and morphological correlates in patients bearing growth hormone-secreting pituitary tumors with or without constitutively active adenylyl cyclase. J Clin Endocrinol Metab 1990;71:1421-6.
10. Kontogeorgos G, Asa SL, Kovacs K, Smyth HS, Singer W. Production of α-subunit of glycoprotein hormones by pituitary somatotroph adenomas in vitro. Acta Endocrinol (Copenh) 1993;129:565-72.
11. Sano T, Ohshima T, Yamada S. Expression of glycoprotein hormones and intracytoplasmic distribution of cytokeratin in growth hormone-producing pituitary adenomas. Pathol Res Pract 1991;187:530-3.
12. Ezzat S, Kontogeorgos G, Redelmeier DA, Horvath E, Harris AG, Kovacs K. In vivo responsiveness of morphological variants of growth hormone-producing pituitary adenomas to octreotide. Eur J Endocrinol 1995;133:686-90.
13. Bhayana S, Booth GL, Asa SL, Kovacs K, Ezzat S. The implication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly. J Clin Endocrinol Metab 2005;90:6290-5.
14. Asa SL, Coschigano KT, Bellush L, Kopchick JJ, Ezzat S. Evidence for growth hormone (GH) autoregulation in pituitary somatotrophs in GH antagonist-transgenic mice and GH receptor-deficient mice. Am J Pathol 2000;156:1009-15.
15. Neumann PE, Goldman JE, Horoupian DS, Hess MA. Fibrous bodies in growth hormone-secreting adenomas contain cytokeratin filaments. Arch Pathol Lab Med 1985;109:505-8.
16. Chetty R, Asa SL. Pancreatic endocrine tumour with cytoplasmic keratin whorls. Is the term "rhabdoid" appropriate? J Clin Pathol 2004;57:1106-10.
17. DeLellis RA, Lloyd RV, Heitz PU, Eng C. Pathology and genetics of tumours of endocrine organs. WHO classification of tumours. Lyons (France): IARC Press; 2004.
18. Ezzat S, Zheng L, Winer D, Asa SL. Targeting N-cadherin through fibroblast growth factor receptor-4: distinct pathogenetic and therapeutic implications. Mol Endocrinol 2006;20:2965-75.
19. Kohlhuber F, Rogers NC, Watling D, et al. A JAK1/JAK2chimera can sustain α and γ interferon responses. Mol Cell Biol 1997;17:695-706.
20. Jiang J, Liang L, Kim SO, Zhang Y, Mandler R, Frank SJ. Growth hormone-dependent tyrosine phosphorylation of a GH receptor-associated high molecular WEIGHT protein immunologically related to JAK2. Biochem Biophys Res Commun 1998;253:774-9.
21. Loesch K, Deng L, Cowan JW, et al. Janus kinase 2 influences growth hormone receptor metalloproteolysis. Endocrinology 2006;147:2839-49.
22. Zhang Y, Guan R, Jiang J, et al. Growth hormone (GH)-induced dimerization inhibits phorbol ester-stimulated GH receptor proteolysis. J Biol Chem 2001;276:24565-73.
23. Chen C, Brinkworth R, Waters MJ. The role of receptor dimerization domain residues in growth hormone signaling. J Biol Chem 1997;272:5133-40.
24. Frank SJ, Gilliland G, Kraft AS, Arnold CS. Interaction of the growth hormone receptor cytoplasmic domain with the JAK2t yrosine kinase. Endocrinology 1994;135:2228-39.
25. Zhang Y, Jiang J, Kopchick JJ, Frank SJ. Disulfide linkage of growth hormone (GH) receptors (GHR) reflects GH-induced GHR dimerization. Association of JAK2with the GHR is enhanced by receptor dimerization. J Biol Chem 1999;274:33072-84.
26. Wang X, He K, Gerhart M, et al. Metalloprotease-mediated GH receptor proteolysis and GHBP shedding. Determination of extracellular domain stem region cleavage site. J Biol Chem 2002;277:50510-9.
27. Jiang J, Wang X, He K, et al. A conformationally sensitive GHR [growth hormone (GH) receptor] antibody: impact on GH signaling and GHR proteolysis. Mol Endocrinol 2004;18:2981-96.
28. Wang X, He K, Gerhart M, et al. Reduced proteolysis of rabbit growth hormone (GH) receptor substituted with mouse GH receptor cleavage site. Mol Endocrinol 2003;17:1931-43.
29. He K, Wang X, Jiang J, et al. Janus kinase 2 determinants for growth hormone receptor association, surface assembly, and signaling. Mol Endocrinol 2003;17:2211-27.
30. Vallar L, Spada A, Giannattasio G. Altered Gs and adenylate cyclase activity in human GH-secreting pituitary adenomas. Nature 1987;330:566-8.
31. Bass SH, Mulkerrin MG, Wells JA. A systematic mutational analysis of hormone-binding determinants in the human growth hormone receptor. Proc Natl Acad Sci U S A 1991;88:4498-502.
32. Leung DW, Spencer SA, Cachianes G, et al. Growth hormone receptor and serum binding protein: purification, cloning and expression. Nature 1987;330:537-43.
33. Colosi P, Wong K, Leong SR, Wood WI. Mutational analysis of the intracellular domain of the human growth hormone receptor. J Biol Chem 1993;268:12617-23.
34. Wang YD, Wood WI. Amino acids of the human growth hormone receptor that are required for proliferation and Jak-STAT signaling. Mol Endocrinol 1995;9:303-11.
35. He K, Loesch K, Cowan JW, et al. Janus kinase 2 enhances the stability of the mature growth hormone receptor. Endocrinology 2005;146:4755-65.
36. Shevah O, Galli-Tsinopoulou A, Rubinstein M, Nousia-Arvanitakis S, Laron Z. Classical phenotype of Laron syndrome in a girl with a heterozygous mutation and heterozygous polymorphism of the growth hormone receptor gene. J Pediatr Endocrinol Metab 2004;17:371-4.
37. Chen X, Song F, Dai Y, Bao X, Jin Y. A novel mutation of the growth hormone receptor gene (GHR) in a Chinese girl with Laron syndrome. J Pediatr Endocrinol Metab 2003;16:1183-9.
38. Putzolu M, Meloni A, Loche S, Pischedda C, Cao A, Moi P. A homozygous nonsense mutation of the human growth hormone receptor gene in a Sardinian boy with Laron-type dwarfism. J Endocrinol Invest 1997;20:286-8.
39. Kola B, Korbonits M, Diaz-Cano S, et al. Reduced expression of the growth hormone and type 1 insulin-like growth factor receptors in human somatotroph tumours and an analysis of possible mutations of the growth hormone receptor. Clin Endocrinol (Oxf) 2003;59:328-38.
40. Trainer PJ, Drake WM, Katznelson L, et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 2000;342:1171-7.
41. Chen WY, Chen N-Y, Yun J, Wagner TE, Kopchick JJ. In vitro and in vivo studies of antagonistic effects of human growth hormone analogs. J Biol Chem 1994;269:15892-7.
42. Thorner MO, Strasburger CJ, Wu Z, et al. Growth hormone (GH) receptor blockade with a PEG-modified GH (B2036-PEG) lowers serum insulin-like growth factor-I but does not acutely stimulate serum GH. J Clin Endocrinol Metab 1999;84:2098-103.
43. Veldhuis JD, Bidlingmaier M, Anderson SM, Wu Z, Strasburger CJ. Lowering total plasma insulin-like growth factor I concentrations by way of a novel, potent, and selective growth hormone (GH) receptor antagonist, pegvisomant (B2036-peg), augments the amplitude of GH secretory bursts and elevates basal/nonpulsatile GH release in healthy women and men. J Clin Endocrinol Metab 2001;86:3304-10.
44. Elias KA, Weiner RI. Direct arterial vascularization of estrogen-induced prolactin-secreting anterior pituitary tumors. Proc Natl Acad Sci USA 1984;81:4549-53.
45. Harding PA, Wang XZ, Kelder B, Souza S, Okada S, Kopchick JJ. In vitro mutagenesis of growth hormone receptor Asn-linked glycosylation sites. Mol Cell Endocrinol 1994;106:171-80.